Milestone Scientific Reports Independent Industry Coverage of the CompuFlo(R) Epidural System in OBG Management Magazine

LIVINGSTON, NJ -- (Marketwired) -- 04/02/18 -- Milestone Scientific Inc. (NYSE American: MLSS) (NYSE MKT: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, reported the following independent industry trade coverage of the CompuFlo® Epidural system in an article entitled "Pressure-Sensing Technology For Epidurals" in the Product Update column, in the March issue of OBG Management, a leading publication in the ObGyn specialty addressing patient care and practice management under one cover. OBG reports on new and existing obstetric and gynecologic procedures, treatments, and surgical techniques; and present physicians' evidence-based approaches to treatment.

Publication: OBG Management is a free, BPA-audited print and digital publication distributed to just over 124,000 OB/GYN clinicians six times a year.


This coverage reflects the recogniton and continuing interest in the CompuFlo® Epidural System as an innovative technology that provides an objective, real-time and documented confirmation of epidural space location during epidural anesthesia and analgesia procedures. Publication in this specialty clinical journal highlights the importance of this new technology for obstetric patients and practitioners.

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs and develops innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone's proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website:

Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, successfully commercialize its medical devices, achieve expected revenues, and obtain incremental regulatory approvals and otherwise achieve future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2016. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

David Waldman or Natalya Rudman
Crescendo Communications, LLC
Tel: 212-671-1020

Source: Milestone Scientific, Inc.